Danaher Corporation

$255.56
(as of Oct 23, 11:34 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Danaher Corporation

Stock Price
$255.56
Ticker Symbol
DHR
Exchange
NYSE

Industry Information for Danaher Corporation

Sector
Healthcare
Industry
Diagnostics & Research

Company Description for Danaher Corporation

Country
USA
Full Time Employees
61,000

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.

Fundamentals for Danaher Corporation

Market Capitalization
$188,699,803,648
EBITDA
$7,459,999,744
Dividends per Share
$0
P/E Ratio
48.03
Forward P/E Ratio
30.96
Earnings per Share
$5.44
Earnings per Share Estimate Next Year
$8.63
Profit Margin
17.83%
Shares Outstanding
722,212,992
Percent Owned by Insiders
11.00%
Percent Owned by Institutions
82.71%
52-Week High
$281.43
52-Week Low
$181.33

Technical Indicators for Danaher Corporation

50-Day Moving Average
$270.76
200-Day Moving Average
$255.52
RSI
38.38
5.65

Analyst Ratings for Danaher Corporation

Strong Buy
15
Buy
3
Hold
8
Sell
0
Strong Sell
0

News About Danaher Corporation

Oct 18, 2024, 11:46 AM EST
Danaher Corporation DHR is scheduled to release third-quarter 2024 results on Oct. 22, before market open. See more.
Oct 17, 2024, 9:15 AM EST
Wall Street analysts expect Danaher (DHR) to post quarterly earnings of $1.56 per share in its upcoming report, which indicates a year-over-year decline of 22.8%. See more.
Oct 11, 2024, 9:20 AM EST
Danaher Corporation DHR is poised to benefit from strength in its clinical diagnostics business, backed by growth in Leica Biosystems and Beckman Colter Diagnostics units. See more.
Oct 4, 2024, 1:10 PM EST
We recently made a list of Goldman Sachs’ Top Fund Manager Stock Picks: 25 Best Overweight Stocks. See more.